ArticleCancer medicine2026
Management and Prognosis of HCC Patients With Elevated Tumor Markers but no Imaging Recurrence After Radiofrequency Ablation.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsHCC frequently recurs after curative treatment, requiring surveillance with imaging and tumor markers. Some patients, however, present with persistent tumor marker elevation despite no radiologic recurrence evidence. This study evaluated outcomes following radiofrequency ablation (RFA) in such cases.
methodsWe retrospectively analyzed 1620 patients who achieved complete ablation for primary HCC during 1999-2015. Surveillance included quarterly imaging and serum tumor markers, alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP). Patient characteristics at tumor marker elevation and recurrent HCC characteristics were compared between the early recurrence group (recurrence within 180 days of tumor marker elevation) and the late recurrence group (recurrence after 180 days of tumor marker elevation). We also estimated post-recurrence survival using the Kaplan-Meier method.
resultsTumor marker elevation occurred in 907 cases in 509 patients. Recurrence was detected in 886 cases: 707 in the early and 179 in the late recurrence groups. The median (interquartile range) interval between marker elevation and recurrence was 89.0 (81.0-97.0) days. At tumor marker elevation, AFP ≥ 20 ng/mL was more frequent in the early versus late recurrence group (71.0% vs. 58.1%, p < 0.01), as was AFP ≥ 200 ng/mL (29.4% vs. 20.1%, p = 0.02). AFP-L3 ≥ 15% (60.0% vs. 62.6%, p = 0.58) and DCP ≥ 200 mAU/mL (19.7% vs. 16.2%, p = 0.34) showed no significant differences between groups. Recurrence patterns, including number of tumors, vascular invasion, distant metastasis, and tumor size, were comparable between groups. Local cure was achieved in 83.5% and 78.8% of the early and late recurrence groups, respectively, with no significant difference (p = 0.17). Median post-recurrence survival was 3.55 years for the early versus 3.31 years for the late recurrence group (p = 0.2).
conclusionsEven when HCC was undetected on imaging despite elevated tumor markers, many recurrence cases were subsequently detected, and curative treatment was possible through appropriate surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.